Immutep to Evaluate Efti in Triple Combination Therapy Phase I Study with Chemotherapy and an anti-PD-1 Therapy

NEXT STORY
OPKO Health to Develop and Commercialize RAYALDEE® in Greater China with Nicoya Therapeutics
PREV STORY
The United States IVD Market 2021-2026: COVID-19 as a Catalyst for an Acceleration in Research and Development
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Aravive Biologics Initiates Phase 1b Portion of Phase 1b/2 Clinical Trial of AVB-S6-500 in Platinum-Resistant Recurrent Ovarian Cancer

HOUSTON, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical ...

author_avatar
NASDAQ Market News

Post-Hospital MRSA Infections Reduced By 30 Percent Through Use of Antiseptic Soap, Mouthwash, and Antibiotic Nasal Ointment

Rockville, Md., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Methicillin-resistant Staphylococcus aureus (MRSA) infections and ...

author_avatar
NASDAQ Market News

Axsome Therapeutics Initiates Phase 2 Trial of AXS-12 in Narcolepsy

Topline results anticipated in 2Q 2019 NEW YORK, Jan. 30, 2019 (GLOBE NEWSWIRE) -- ...

author_avatar
NASDAQ Market News